Kymera Director Sells 2,500 Shares, Exercises Options Ahead of Analyst Upgrades
Kymera Therapeutics director Pamela Esposito completed a set of transactions on March 20, 2026, selling 2,500 shares for $197,877 while exercising options to acquire 2,500 shares at $49.10. The activity comes as analysts raise price targets following the company's fourth-quarter and full-year 2025 results and ahead of a planned KT-621 data presenta…